Nothing Special   »   [go: up one dir, main page]

CU20150066A7 - TRICYCLIC COMPOUNDS TO INHIBIT THE CFTR CHANNEL - Google Patents

TRICYCLIC COMPOUNDS TO INHIBIT THE CFTR CHANNEL

Info

Publication number
CU20150066A7
CU20150066A7 CUP2015000066A CU20150066A CU20150066A7 CU 20150066 A7 CU20150066 A7 CU 20150066A7 CU P2015000066 A CUP2015000066 A CU P2015000066A CU 20150066 A CU20150066 A CU 20150066A CU 20150066 A7 CU20150066 A7 CU 20150066A7
Authority
CU
Cuba
Prior art keywords
pharmaceutically acceptable
tricyclic compounds
cftr channel
inhibit
acceptable salt
Prior art date
Application number
CUP2015000066A
Other languages
Spanish (es)
Inventor
Mahbub Ahmed
Alexander Ashall-Kelly
Louisa Gueritz
Jeffrey Mckenna
Joseph Mckenna
Simon Mutton
Rakesh Parmar
Jon Shepherd
Paul Wright
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50030372&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU20150066(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CU20150066A7 publication Critical patent/CU20150066A7/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención proporciona compuestos tricíclicos heterocíclicos sustituidos de la fórmula (I) o una sal farmacéuticamente aceptable del mismo ESPACIO PARA FÓRMULA activos como inhibidores del canal CFTR, y útiles en el tratamiento de enfermedad poliquística del riñón y diarrea secretora. La presente invención proporciona una composición farmacéutica que comprende una cantidad terapéuticamente efectiva de un compuesto tricíclico heterocíclico sustituido o una sal farmacéuticamente aceptable del mismo, y uno o más vehículos farmacéuticamente aceptables.The present invention provides substituted heterocyclic tricyclic compounds of the formula (I) or a pharmaceutically acceptable salt of the same FORMULA SPACE active as CFTR channel inhibitors, and useful in the treatment of polycystic kidney disease and secretory diarrhea. The present invention provides a pharmaceutical composition comprising a therapeutically effective amount of a heterocyclic substituted tricyclic compound or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers.

CUP2015000066A 2012-12-19 2015-06-19 TRICYCLIC COMPOUNDS TO INHIBIT THE CFTR CHANNEL CU20150066A7 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261739335P 2012-12-19 2012-12-19
US201361906141P 2013-11-19 2013-11-19
PCT/IB2013/061043 WO2014097148A1 (en) 2012-12-19 2013-12-17 Tricyclic compounds for inhibiting the cftr channel

Publications (1)

Publication Number Publication Date
CU20150066A7 true CU20150066A7 (en) 2015-11-27

Family

ID=50030372

Family Applications (1)

Application Number Title Priority Date Filing Date
CUP2015000066A CU20150066A7 (en) 2012-12-19 2015-06-19 TRICYCLIC COMPOUNDS TO INHIBIT THE CFTR CHANNEL

Country Status (25)

Country Link
US (2) US9359381B2 (en)
EP (1) EP2935278B1 (en)
JP (1) JP6284546B2 (en)
KR (1) KR20150097660A (en)
CN (1) CN105143230B (en)
AP (1) AP2015008539A0 (en)
AR (1) AR094122A1 (en)
AU (1) AU2013365739A1 (en)
BR (1) BR112015014292A2 (en)
CA (1) CA2895660A1 (en)
CL (1) CL2015001730A1 (en)
CR (1) CR20150325A (en)
CU (1) CU20150066A7 (en)
EA (1) EA201591177A1 (en)
ES (1) ES2628369T3 (en)
HK (1) HK1209741A1 (en)
IL (1) IL239389A0 (en)
MX (1) MX2015007939A (en)
PE (1) PE20151055A1 (en)
PH (1) PH12015501386A1 (en)
SG (1) SG11201504594QA (en)
TN (1) TN2015000279A1 (en)
TW (1) TW201429974A (en)
UY (1) UY35211A (en)
WO (1) WO2014097148A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6165733B2 (en) 2011-09-16 2017-07-19 ノバルティス アーゲー N-substituted heterocyclylcarboxamides
WO2014097148A1 (en) 2012-12-19 2014-06-26 Novartis Ag Tricyclic compounds for inhibiting the cftr channel
JP6284545B2 (en) * 2012-12-19 2018-02-28 ノバルティス アーゲー Tricyclic compounds as CFTR inhibitors
US10597496B2 (en) 2014-09-19 2020-03-24 Momentive Performance Materials Inc. Platinum (II) diene complexes for controlled siloxane crosslinking
CN106478558B (en) * 2016-10-17 2019-03-29 天津雅奥科技发展有限公司 A kind of synthetic method of 4- methylol-dihydro-furan -2 (3H) -one
AU2022265718A1 (en) 2021-04-29 2023-11-02 Novartis Ag Deubiquitinase-targeting chimeras and related methods
CN117654560B (en) * 2023-12-01 2024-06-04 安徽泽升科技股份有限公司 Method for continuously preparing nitro compound by oxidizing amino

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1207161B1 (en) 1999-08-25 2006-01-18 Banyu Pharmaceutical Co., Ltd. Novel isoindole derivatives
JP2002255967A (en) 2001-02-27 2002-09-11 Banyu Pharmaceut Co Ltd Treating agent for diabetes mellitus, preventing agent for chronic complication of diabetes mellitus or treating agent for obesity consisting of isoindole derivative as active ingredient
JP2007524596A (en) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド Co-crystal pharmaceutical composition
CN101668751A (en) 2006-12-12 2010-03-10 先灵公司 aspartyl protease inhibitors
US20110015137A1 (en) * 2007-07-05 2011-01-20 Trustees Of Boston University Reca inhibitors and their uses as microbial inhibitors or potentiators of antibiotic activity
CA2709784A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2011019737A1 (en) 2009-08-10 2011-02-17 The Regents Of The University Of California Pyrimido-pyrrolo-quinoxalinedione inhibitors of cystic fibrosis transmembrane conductance regulator protein and uses therefor
US9062073B2 (en) * 2011-05-27 2015-06-23 The Regents Of The University Of California Pyrimido-pyrrolo-oxazine-dione compound inhibitors of the cystic fibrosis transmembrane conductance regulator protein and uses therefor
WO2014097148A1 (en) 2012-12-19 2014-06-26 Novartis Ag Tricyclic compounds for inhibiting the cftr channel
JP6284545B2 (en) * 2012-12-19 2018-02-28 ノバルティス アーゲー Tricyclic compounds as CFTR inhibitors

Also Published As

Publication number Publication date
TN2015000279A1 (en) 2016-10-03
WO2014097148A9 (en) 2015-02-19
CN105143230A (en) 2015-12-09
JP6284546B2 (en) 2018-02-28
PH12015501386A1 (en) 2015-09-02
BR112015014292A2 (en) 2017-07-11
PE20151055A1 (en) 2015-08-05
SG11201504594QA (en) 2015-07-30
KR20150097660A (en) 2015-08-26
AU2013365739A1 (en) 2015-07-09
MX2015007939A (en) 2016-03-11
AR094122A1 (en) 2015-07-08
CN105143230B (en) 2017-06-09
IL239389A0 (en) 2015-07-30
US20140171417A1 (en) 2014-06-19
JP2016509579A (en) 2016-03-31
ES2628369T3 (en) 2017-08-02
CA2895660A1 (en) 2014-06-26
WO2014097148A1 (en) 2014-06-26
CR20150325A (en) 2015-08-10
US9359381B2 (en) 2016-06-07
EA201591177A1 (en) 2015-11-30
UY35211A (en) 2014-07-31
US20150336986A1 (en) 2015-11-26
EP2935278B1 (en) 2017-03-15
CL2015001730A1 (en) 2015-08-28
AP2015008539A0 (en) 2015-06-30
HK1209741A1 (en) 2016-04-08
TW201429974A (en) 2014-08-01
EP2935278A1 (en) 2015-10-28

Similar Documents

Publication Publication Date Title
CU20150066A7 (en) TRICYCLIC COMPOUNDS TO INHIBIT THE CFTR CHANNEL
CU24397B1 (en) DERIVATIVES OF PIPERIDINIL-INDOL AS INHIBITORS OF THE COMPLEMENT FACTOR B
DOP2014000152A (en) BROMODOMINIUM INHIBITORS
CR20150078A (en) 1,4-DISPOSED PIRIDAZINE ANALOGS AND METHODS FOR THE TREATMENT OF CONDITIONS RELATED TO THE DEFICIENCY OF SMN
NI201600058A (en) RING-FUSED BICYCLIC PYRIDYL-DERIVED COMPOUNDS AS FGFR4 INHIBITORS
CR20130487A (en) 1,3-oxazines as inhibitors of BACE1 and / or BACE2
DOP2016000085A (en) AMINO-HETEROARIL-BENZAMIDAS AS CINASA INHIBITORS
CO6620055A2 (en) Certain amino-pyrimidines, compositions thereof and methods for the use thereof
CL2013002417A1 (en) Compounds derived from fluoropyridinone; pharmaceutical composition comprising them; and its use in the treatment of bacterial infections.
CR20150418A (en) TETRAHYDROPIRROLOTIAZINE COMPOUNDS
MX345928B (en) Therapeutically active compositions and their methods of use.
CU24350B1 (en) DERIVATIVES OF 5-HETEROARIL-4-FENIL-4,5-DIHIDROPIRROLO (3,4-c) PIRAZOL-6-ONA ACTIVE AS BET INHIBITORS
CR20110634A (en) 3 KINASE PHOSPHINOSITI INHIBITORS AND / OR RAPAMYCIN MAMMAL OBJECTIVE
CR20140361A (en) PDE9 INHIBITORS WITH BASIC STRUCTURE OF IMIDAZOTRIAZINONA
UY34960A (en) DIHYDROPIRIDONE P1 AS INHIBITORS OF THE XIA FACTOR
ECSP12011799A (en) ESPIROPIPERIDINE AND PHARMACEUTICAL USE OF THE SAME COMPOUNDS
UY32490A (en) BETA-SECRETASA INHIBITORS
DOP2015000201A (en) AZABENCIMIDAZOL COMPOUNDS AS INHIBITORS OF PDEN4 ISOENZIMAS FOR THE TREATMENT OF THE CNS AND OTHER DISORDERS
CR20140036A (en) INHIBITOR COMPOUND OF THE SIGNALING OF THE NOTCH TRAJECTORY
CU20160192A7 (en) INDANO AND INDOLINA DERIVATIVES USEFUL AS ACTIVATORS OF THE SOLUBLE CYCLING GUANILATE
EA202090098A1 (en) PHARMACEUTICAL COMPOSITIONS OF THERAPEUTICALLY ACTIVE COMPOUNDS
CR20150419A (en) SUBSTITUTED DERIVATIVES OF PHOSPHONE BISPHENILE ACID AS INHIBITORS OF THE NEP
UY35209A (en) TRICYCLIC COMPOUNDS
BR112014030720A8 (en) compound, pharmaceutical composition and uses of fbx03 inhibitors
CO2019005165A2 (en) Pyridone compound as c-met inhibitor